John Ackerman Sells 1,103,364 Shares of Guardian Pharmacy Services (NYSE:GRDN) Stock

Guardian Pharmacy Services, Inc. (NYSE:GRDN) Director John Ackerman sold 1,103,364 shares of the stock in a transaction on Friday, March 20th. The stock was sold at an average price of $29.68, for a total transaction of $32,747,843.52. Following the transaction, the director owned 345,123 shares in the company, valued at approximately $10,243,250.64. This trade represents a 76.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Guardian Pharmacy Services Trading Down 3.0%

GRDN stock opened at $35.41 on Friday. Guardian Pharmacy Services, Inc. has a 1 year low of $19.17 and a 1 year high of $38.12. The company has a fifty day simple moving average of $32.74 and a 200 day simple moving average of $29.91. The firm has a market cap of $2.24 billion, a PE ratio of 45.98 and a beta of 0.86.

Guardian Pharmacy Services (NYSE:GRDN) last posted its earnings results on Wednesday, March 11th. The company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.27 by $0.10. Guardian Pharmacy Services had a net margin of 3.40% and a return on equity of 31.64%. The firm had revenue of $397.62 million for the quarter, compared to the consensus estimate of $390.04 million. Guardian Pharmacy Services’s revenue was up 17.4% compared to the same quarter last year. As a group, analysts forecast that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GRDN has been the topic of a number of recent analyst reports. Raymond James Financial reissued an “outperform” rating and issued a $40.00 price objective on shares of Guardian Pharmacy Services in a research note on Thursday, March 12th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Guardian Pharmacy Services in a research report on Monday, December 29th. Zacks Research upgraded Guardian Pharmacy Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 18th. Oppenheimer lifted their price target on shares of Guardian Pharmacy Services from $35.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, March 12th. Finally, Stephens raised their target price on shares of Guardian Pharmacy Services from $35.00 to $36.00 and gave the company an “overweight” rating in a research note on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $38.00.

Key Stories Impacting Guardian Pharmacy Services

Here are the key news stories impacting Guardian Pharmacy Services this week:

• Positive Sentiment: Q3 / latest quarter: GRDN beat EPS and revenue estimates (revenue +17.4% YoY), which supports growth expectations. MarketBeat GRDN summary
• Positive Sentiment: Analyst momentum: several firms (Truist, Raymond James, Oppenheimer, Stephens, Zacks) have raised targets or ratings recently, leaving a buy/strong-buy consensus and a ~$38 average target. Analyst coverage
• Neutral Sentiment: Institutional holders: several funds (Vanguard, Wellington, Brown Advisory, Franklin, Valiant) have recently adjusted positions; this shows continuing institutional interest but mixed flows. Holders data
• Neutral Sentiment: Market writeups flagged “major insider exodus,” useful for context but not new filings by itself. TipRanks article
• Negative Sentiment: Director Thomas J. Salentine, Jr. sold 3,570,677 shares at ~$29.68 (~$106.0M), a ~44% reduction — a large block that likely pressured the stock. SEC filing
• Negative Sentiment: Director William E. Bindley sold 3,570,677 shares at ~$29.68 (~$106.0M), a ~44% reduction — another very large director sale. SEC filing
• Negative Sentiment: Director John Ackerman sold 1,103,364 shares at ~$29.68 (~$32.7M), a ~76% reduction in his stake. SEC filing
• Negative Sentiment: Officer Fred Burke sold 671,432 shares at ~$29.68 (~$19.9M), a ~44% cut to his position. SEC filing
• Negative Sentiment: Insider Kendall Forbes sold 346,672 shares at ~$29.68 (~$10.3M), reducing her holding by ~43%. SEC filing
• Negative Sentiment: Insider David K. Morris sold 187,855 shares at ~$29.68 (~$5.6M), cutting his position by ~42%. SEC filing
• Negative Sentiment: Major shareholder Equity Fund L.P. (Cardinal) sold 275,728 shares at ~$29.68 (~$8.2M), a ~44% stake reduction — signals significant institutional unloading. SEC filing

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. boosted its stake in Guardian Pharmacy Services by 35.6% during the fourth quarter. Invesco Ltd. now owns 14,175 shares of the company’s stock worth $427,000 after buying an additional 3,718 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Guardian Pharmacy Services during the 4th quarter valued at about $348,000. Valiant Capital Management L.P. boosted its position in shares of Guardian Pharmacy Services by 15.8% during the 4th quarter. Valiant Capital Management L.P. now owns 1,232,463 shares of the company’s stock valued at $37,085,000 after acquiring an additional 167,741 shares in the last quarter. Susquehanna Portfolio Strategies LLC acquired a new position in Guardian Pharmacy Services in the fourth quarter worth about $333,000. Finally, Occudo Quantitative Strategies LP raised its position in Guardian Pharmacy Services by 94.8% in the fourth quarter. Occudo Quantitative Strategies LP now owns 31,266 shares of the company’s stock worth $941,000 after purchasing an additional 15,218 shares in the last quarter.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.